Publications by the researcher in collaboration with Juan José Lasarte (20)

2025

  1. Discovery and preclinical development of a SdAb-based CAR-T technology for targeting CD33 in AML

    Molecular Therapy Oncology, Vol. 33, Núm. 1

  2. Phosphatidylserine as a tumor target for CAR-T cell therapy

    Journal for ImmunoTherapy of Cancer, Vol. 13, Núm. 2

2024

  1. Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma

    Blood Advances, Vol. 8, Núm. 21, pp. 5479-5492

  2. Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model

    Journal for immunotherapy of cancer, Vol. 12, Núm. 7

2023

  1. FOXP3 expression diversifies the metabolic capacity and enhances the efficacy of CD8 T cells in adoptive immunotherapy of melanoma

    Molecular Therapy, Vol. 31, Núm. 1, pp. 48-65

  2. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia

    Frontiers in Immunology, Vol. 14

  3. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

  4. The transcriptional regulator Sin3A balances IL-17A and Foxp3 expression in primary CD4 T cells

    EMBO Reports, Vol. 24, Núm. 5

2022

  1. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

    Science Advances, Vol. 8, Núm. 39

  2. Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma

    Frontiers in Immunology, Vol. 13

  3. Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy

    OncoImmunology, Vol. 11, Núm. 1

  4. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 8

2021

  1. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential

    Frontiers in Immunology, Vol. 12

  2. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

2020

  1. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  2. Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression

    Journal of Urology

2019

  1. Improving immunotherapy through chromatin remodelers inhibitors in bladder cancer

    Dianas: revista de dianas terapéuticas, Vol. 8, Núm. 1

  2. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

    Nature Medicine

2018

  1. Inhibition of a G9a-Ezh2 network triggers an immune-mediated bladder cancer regression

    Dianas: revista de dianas terapéuticas, Vol. 7, Núm. 1

2017

  1. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

    Nature Communications, Vol. 8